Current opinion in neurology
-
Curr. Opin. Neurol. · Apr 2006
ReviewBrain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures?
Scheduled and responsive direct brain stimulation may be an effective and safe therapy for medically intractable epilepsy. ⋯ Direct brain stimulation appears to be safe and may be efficacious in treating medically intractable epilepsy. The optimal location (deep brain or cortical) and characteristics of the stimulation (frequency, current, duration), and whether stimulation should be focal or responsive are still to be determined. If ongoing studies of a deep brain stimulator and of a cranially implanted responsive neurostimulator demonstrate effectiveness, then neurostimulation may become available as adjunctive therapy for medically intractable epilepsy.
-
This review considers the current role of magnetoencephalography in clinical epileptology. ⋯ Magnetoencephalography has been developed to a valuable noninvasive tool in clinical epileptology. The development of approaches which take into account both magnetoencephalography and electroencephalography simultaneously should provide more useful information in the future.
-
Curr. Opin. Neurol. · Feb 2006
ReviewMotor learning: its relevance to stroke recovery and neurorehabilitation.
Much of neurorehabilitation rests on the assumption that patients can improve with practice. This review will focus on arm movements and address the following questions: (i) What is motor learning? (ii) Do patients with hemiparesis have a learning deficit? (iii) Is recovery after injury a form of motor learning? (iv) Are approaches based on motor learning principles useful for rehabilitation? ⋯ Motor learning mechanisms are operative during spontaneous stroke recovery and interact with rehabilitative training. For optimal results, rehabilitation techniques should be geared towards patients' specific motor deficits and possibly combined, for example, CIMT with VR. Two critical questions that should always be asked of a rehabilitation technique are whether gains persist for a significant period after training and whether they generalize to untrained tasks.
-
Curr. Opin. Neurol. · Oct 2005
ReviewNeuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Some of the 20% of myasthenia gravis patients who do not have antibodies to acetylcholine receptors (AChRs) have antibodies to muscle specific kinase (MuSK), but a full understanding of their frequency, the associated clinical phenotype and the mechanisms of action of the antibodies has not yet been achieved. Moreover, some patients do not respond well to conventional corticosteroid therapy. Here we review recent clinical and experimental studies on MuSK antibody associated myasthenia gravis, and summarize the results of newer treatments for myasthenia gravis. ⋯ MuSK antibodies define a form of myasthenia gravis that can be difficult to diagnose, can be life threatening and may require additional treatments. An improved AChR antibody assay may be helpful in patients without AChR or MuSK antibodies. Clinical trials of drugs in other neuroimmunological diseases may help to guide the treatment of myasthenia gravis.